You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Genes, HER2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

    Recruiting
    • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
    • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
    • Montpellier, France
    • +1 more
    Nov 16, 2022

    Homologous Recombination-related Genesmutationsand HRD in Breast

    Not yet recruiting
    • Breast Cancer
    • HER2-low Breast Cancer
    • Standard Management
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Jul 18, 2022

    Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

    Active, not recruiting
    • Advanced Breast Cancer
    • +2 more
    • Talazoparib Tosylate
    • Stanford, California
      Stanford University Hospitals and Clinics
    Nov 16, 2022

    Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

    Recruiting
    • Salivary Gland Cancer
    • +3 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Feb 18, 2022

    Advanced Pancreatic Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 Trial in

    Recruiting
    • Advanced Pancreatic Carcinoma
    • +27 more
    • Gainesville, Florida
    • +3 more
    Jan 3, 2023

    Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

    Not yet recruiting
    • Breast Cancer
    • HER2-positive Breast Cancer
    • São Paulo, Brazil
      Centro Paulista de Oncologia (Oncoclínicas)
    Oct 3, 2023

    HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • PIK3CA analysis
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    18F-HER2 PET Trial in Hangzhou (18F-HER2 PET)

    Not yet recruiting
    • 18F-HER2 PET
    • 18F-HER2 PET
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Zhejiang University School of med
    Aug 2, 2023

    HER2 Expression and Clinical Pathological Characteristics in

    Recruiting
    • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
    • Collect HER2 expression in prostate cancer patients
    • Jinan, Shandong, China
      Qilu hospital
    Nov 17, 2023

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

      Not yet recruiting
      • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
      • SHR-A1811
      • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
      • (no location specified)
      Nov 6, 2023

      HER2-positive Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      HER2-low Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

      Not yet recruiting
      • Breast Cancer
      • +3 more
      • (no location specified)
      Aug 4, 2023

      HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

      Recruiting
      • HR Positive/HER2 Low Expression Metastatic Breast Cancer
      • Disitamab vedotin
      • Endocrine therapy
      • Guangzhou, Guangdong, China
      • +2 more
      Jun 19, 2023

      Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

      Not yet recruiting
      • Solid Tumor
      • Intravenous infusion anti-HER2-CAR-T cell
      • Shenyang, Liaoning, China
        Phase I Clinical Trials Center Of The First Hospital of China Me
      Oct 30, 2023

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

      Not yet recruiting
      • Breast Cancer
      • Marseille, France
        Institut Paoli Calmettes
      Aug 9, 2023

      HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

      Recruiting
      • HER2-positive Gastric Cancer
      • Immunotherapy
      • Disitamab Vedotin combined with fruquintinib and Tislelizumab
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Aug 8, 2023

      Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Cessation of anti-HER2 treatment
      • Boston, Massachusetts
      • +1 more
      Feb 9, 2023

      Key Genes in Hepatocellular Carcinoma

      Recruiting
      • Hepatocellular Carcinoma
      • None of intervention
      • Hangzhou, Zhejiang, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      Feb 26, 2023

      Survival Rate of HER2-Low Breast Cancer Patients

      Completed
      • HER2 Low Breast Carcinoma
      • immunohistochemistry (IHC) and in situ hybridization (ISH) Test
      • (no location specified)
      Mar 2, 2023

      Advanced NSCLC, EGFR Mutation, HER2 Mutation Trial in Worldwide (BAY2927088_formulation A, BAY2927088_formulation B_1,

      Recruiting
      • Advanced Non-small Cell Lung Cancer
      • +2 more
      • BAY2927088_formulation A
      • +2 more
      • Gilbert, Arizona
      • +75 more
      Jan 16, 2023

      HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

      Not yet recruiting
      • HER2-positive Colorectal Cancer
      • HER2-positive Biliary Tract Cancer
      • Beijing, State*, China
        Peking University cancer hospital & institution
      Aug 2, 2023